Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Multidisciplinary osteoporosis management of post low-energy trauma hip-fracture patients

Skorupski, Nicole MSN, NP-C1,a; Alexander, Ivy M. PhD, APRN, ANP-BC, FAAN1,b

Journal of the American Academy of Nurse Practitioners: January 2013 - Volume 25 - Issue 1 - p 3–10
doi: 10.1111/1745-7599.12002

Purpose: The purpose of this article is to increase awareness of osteoporosis incidence in patients with hip fracture among providers and allied health professionals, to increase osteoporosis recognition and treatment in post hip-fracture patients, and to provide guidance on how to improve continuity of care and collaboration between members of the multidisciplinary healthcare team.

Data sources: Recent evidence from the literature is reviewed to identify effective management strategies for post low-energy trauma hip-fracture patients and prevention of future osteoporotic fracture, regardless of osteoporosis diagnosis prior to the initial fracture.

Conclusions: Despite the availability of accurate screening technologies and highly efficacious antiosteoporosis medications, implementation of these measures for low-energy trauma hip-fracture patients remains critically low. This is because of a number of factors including hesitancy to integrate care across specialty lines, lack of reliable referral systems, and resistance to change. There is also a lack of recognition of the connection between low-energy trauma hip fracture and osteoporosis by many healthcare professionals.

Implications for practice: All members of the multidisciplinary care team are called to action to adopt osteoporosis evaluation and treatment strategies that research has shown to be effective on a larger scale in the post hip-fracture setting.

1 Yale University School of Nursing, New Haven, Connecticut,

aNurse Practitioner

bProfessor, Director of Adult-Gerontological, Family, and Women's Health Nurse Practitioner Primary Care Specialty

Received 25 April 2012; accepted 10 October 2012

Correspondence Ivy M. Alexander, PhD, APRN, ANP-BC, FAAN, PO Box 9740, 100 Church Street South, Suite #200, New Haven, Connecticut 06536-0740. Tel: 203-737-2359; Fax: 203-785-6455; E-mail:

To obtain CE credit for this activity, go to and click on the CE Center. Locate the listing for this article and complete the post-test. Follow the instructions to print your CE certificate.

Disclosures One of the authors (I.A.) has served as a consultant and speaker for Amgen, manufacturer of denosumab. No other relationship exists between any of the authors and any commercial entity of product mentioned in this article that might represent a conflict of interest. There was no solicitation of the authors by any commercial entity to submit the manuscript for publication.

© 2013 John Wiley & Sons, Inc
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website